Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Adaptive, Double-blinded, Placebo Controlled, Randomized, Multi-center Trial to Evaluate the Efficacy, Safety and Tolerability of Intracoronary Infusion of AB-1002 in Adult Subjects With New York Heart Association (NYHA) Class III Heart Failure and Non-ischemic Cardiomyopathy

Next Previous
Trial Profile

A Phase 2, Adaptive, Double-blinded, Placebo Controlled, Randomized, Multi-center Trial to Evaluate the Efficacy, Safety and Tolerability of Intracoronary Infusion of AB-1002 in Adult Subjects With New York Heart Association (NYHA) Class III Heart Failure and Non-ischemic Cardiomyopathy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB 1002 (Primary)
  • Indications Cardiomyopathies; Heart failure
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GenePHIT
  • Sponsors Asklepios BioPharmaceutical

Most Recent Events

  • 29 Aug 2026 According to Ask BIo media release, the company announced presentation of baseline participant characteristics from GenePHIT being presented at the European Society of Cardiology (ESC) Congress, which takes place in Munich, Germany, August 28-31, 2026.
  • 01 Apr 2026 According to a Bayer media release, final patient has been randomized.
  • 01 Apr 2026 According to Asklepios BioPharmaceutical media release, Initial trial results are expected in the first half of 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top